Concizumab is indicated for the treatment of people with hemophilia B who have factor IX inhibitors and require routine prophylaxis to prevent or reduce the frequency of bleeding episodes.[3][4]
^"Alhemo". Therapeutic Goods Administration (TGA). 11 July 2023. Retrieved 10 September 2023.
^"Alhemo (Novo Nordisk Pharmaceuticals Pty Ltd)". Therapeutic Goods Administration (TGA). 28 July 2023. Retrieved 10 September 2023.
^ abcd"Archived copy" (PDF). (PDF) from the original on 17 April 2023. Retrieved 9 June 2023.{{cite web}}: CS1 maint: archived copy as title (link)
^ ab"Summary Basis of Decision for Alhemo". Health Canada. 31 May 2023. Retrieved 9 June 2023.
^ ab"Concizumab Product information". Health Canada. 10 March 2023. from the original on 24 March 2023. Retrieved 9 June 2023.
^"Health Canada approves Alhemo, the first subcutaneous prophylactic treatment for people living with hemophilia B with inhibitors" (Press release). Novo Nordisk Canada. 17 April 2023. Retrieved 9 June 2023 – via Newswire.
^World Health Organization (2013). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 70". WHO Drug Information. 27 (3). hdl:10665/331167.
concizumab, sold, under, brand, name, alhemo, monoclonal, antibody, used, treatment, hemophilia, anti, tissue, factor, pathway, inhibitor, clinical, datatrade, namesalhemopregnancycategoryau, routes, ofadministrationsubcutaneousdrug, classantihemorrhagicatc, c. Concizumab sold under the brand name Alhemo is a monoclonal antibody used for the treatment of hemophilia B 3 It is an anti tissue factor pathway inhibitor 3 ConcizumabClinical dataTrade namesAlhemoPregnancycategoryAU D 1 Routes ofadministrationSubcutaneousDrug classAntihemorrhagicATC codeB02BX10 WHO Legal statusLegal statusAU S4 Prescription only 2 CA only Schedule D 3 4 5 IdentifiersCAS Number1312299 39 0DrugBankDB12820UNII68603V9EAFKEGGD11847Chemical and physical dataFormulaC 6462H 10004N 1712O 2046S 46Molar mass145887 81 g mol 1Concizumab was approved for medical use in Canada in March 2023 5 6 Contents 1 Medical uses 2 Society and culture 2 1 Names 3 ReferencesMedical uses editConcizumab is indicated for the treatment of people with hemophilia B who have factor IX inhibitors and require routine prophylaxis to prevent or reduce the frequency of bleeding episodes 3 4 Society and culture editNames edit Concizumab is the international nonproprietary name 7 References edit Alhemo Therapeutic Goods Administration TGA 11 July 2023 Retrieved 10 September 2023 Alhemo Novo Nordisk Pharmaceuticals Pty Ltd Therapeutic Goods Administration TGA 28 July 2023 Retrieved 10 September 2023 a b c d Archived copy PDF Archived PDF from the original on 17 April 2023 Retrieved 9 June 2023 a href Template Cite web html title Template Cite web cite web a CS1 maint archived copy as title link a b Summary Basis of Decision for Alhemo Health Canada 31 May 2023 Retrieved 9 June 2023 a b Concizumab Product information Health Canada 10 March 2023 Archived from the original on 24 March 2023 Retrieved 9 June 2023 Health Canada approves Alhemo the first subcutaneous prophylactic treatment for people living with hemophilia B with inhibitors Press release Novo Nordisk Canada 17 April 2023 Retrieved 9 June 2023 via Newswire World Health Organization 2013 International nonproprietary names for pharmaceutical substances INN recommended INN list 70 WHO Drug Information 27 3 hdl 10665 331167 Portal nbsp Medicine nbsp This pharmacology related article is a stub You can help Wikipedia by expanding it vte Retrieved from https en wikipedia org w index php title Concizumab amp oldid 1190498334, wikipedia, wiki, book, books, library,
